Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro

Drug Metabolism and Disposition

Volumn 40, Issue 9, 2012, Pages 1778-1784

  Bakken, Gry Vibeke ^a   Molden, Espen ^a,b   Knutsen, Karoline ^b   Lunder, Niclas ^a   Hermann, Monica ^a,b  

^a DIAKONHJEMMET HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXY N DESALKYLQUETIAPINE; BENZYLNIRVANOL; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; DESIPRAMINE; DRUG METABOLITE; ENZYME INHIBITOR; FLUVOXAMINE; KETOCONAZOLE; METHANOL; N DESALKYLQUETIAPINE; N DESALKYLQUETIAPINE SULFOXIDE; PROMAZINE; QUETIAPINE; QUINIDINE; SPARTEINE; SULFAPHENAZOLE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG METABOLISM; DRUG SCREENING; ENZYME INHIBITION; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MASS SPECTROMETRY; PRIORITY JOURNAL;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BIOTRANSFORMATION; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DEALKYLATION; DIBENZOTHIAZEPINES; ENZYME INHIBITORS; HUMANS; HYDROXYLATION; KINETICS; LIVER; MICROSOMES, LIVER; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY; SULFOXIDES; TANDEM MASS SPECTROMETRY;

EID: 84865193567     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.045237     Document Type: Article

References (21)

1. Bakken GV, Rudberg I, Christensen H, Molden E, Refsum H, and Hermann M (2009) Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome B5. Drug Metab Dispos 37:254-258.
2. Bakken GV, Rudberg I, Molden E, Refsum H, and Hermann M (2011) Pharmacokinetic variability of quetiapine and the active metabolite N-desalkylquetiapine in psychiatric patients. Ther Drug Monit 33:222-226.
3. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE, and Loft S (1993) Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 45:1211-1214. (Pubitemid 23098317)
4. Busby WF Jr, Ackermann JM, and Crespi CL (1999) Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450. Drug Metab Dispos 27:246-249. (Pubitemid 29072079)
5. Crewe HK, Lennard MS, Tucker GT, Woods FR, and Haddock RE (1992) The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 34:262-265.
6. Gefvert O, Bergström M, Långström B, Lundberg T, Lindström L, and Yates R (1998) Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacology 135:119-126. (Pubitemid 28055494)
7. Grimm SW, Richtand NM, Winter HR, Stams KR, and Reele SB (2006) Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol 61:58-69. (Pubitemid 43381238)
8. Grimm SW, Stams KR, and Bui K (1997) In vitro prediction of potential metabolic drug interactions for Seroquel (Abstract). Schizophr Res 24:198.
9. Hasselstrøm J and Linnet K (2006) In vitro studies on quetiapine metabolism using the substrate depletion approach with focus on drug-drug interactions. Drug Metabol Drug Interact 21: 187-211.
10. Houston JB and Kenworthy KE (2000) In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab Dispos 28:246-254. (Pubitemid 30137047)
11. Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Rothman RB, and Roth BL (2008) N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 33:2303-2312.
12. Jones HM and Houston JB (2004) Substrate depletion approach for determining in vitro metabolic clearance: time dependencies in hepatocyte and microsomal incubations. Drug Metab Dispos 32:973-982. (Pubitemid 39096058)
13. Klees TM, Sheffels P, Dale O, and Kharasch ED (2005) Metabolism of alfentanil by cytochrome P4503a (cyp3a) enzymes. Drug Metab Dispos 33:303-311. (Pubitemid 40279928)
14. Shimada T, Yamazaki H, Mimura M, Inui Y, and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423. (Pubitemid 24229655)
15. Venkatakrishnan K, Von Moltke LL, and Greenblatt DJ (2001) Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. J Clin Pharmacol 41:1149-1179. (Pubitemid 32983216)
16. von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, and Shader RI (1995) Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 15:125-131.
17. Yamaori S, Yamazaki H, Suzuki A, Yamada A, Tani H, Kamidate T, Fujita K, and Kamataki T (2003) Effects of cytochrome b(5) on drug oxidation activities of human cytochrome P450 (CYP) 3As: similarity of CYP3A5 with CYP3A4 but not CYP3A7. Biochem Pharmacol 66:2333-2340. (Pubitemid 37456741)
18. Yamazaki H, Gillam EM, Dong MS, Johnson WW, Guengerich FP, and Shimada T (1997) Reconstitution of recombinant cytochrome P450 2C10(2C9) and comparison with cytochrome P450 3A4 and other forms: effects of cytochrome P450-P450 and cytochrome P450-b5 interactions. Arch Biochem Biophys 342:329-337. (Pubitemid 27251255)
19. Yamazaki H, Nakamura M, Komatsu T, Ohyama K, Hatanaka N, Asahi S, Shimada N, Guengerich FP, Shimada T, Nakajima M, et al. (2002) Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli. Protein Expr Purif 24:329-337. (Pubitemid 35420057)
20. Yamazaki H, Nakano M, Imai Y, Ueng YF, Guengerich FP, and Shimada T (1996) Roles of cytochrome b5 in the oxidation of testosterone and nifedipine by recombinant cytochrome P450 3A4 and by human liver microsomes. Arch Biochem Biophys 325:174-182.
21. Zhou SF (2009) Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet 48:689-723.